Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:28 AM
Ignite Modification Date:
2025-12-25 @ 2:28 AM
NCT ID:
NCT02086734
Eligibility Criteria:
Inclusion Criteria:
* patients with metastasized renal cell carcinoma treated at the Department of Urology (University of Munich - Grosshadern Campus)
1. with either - Sunitinib (Sutent®), Pazopanib (Votrient ®) bzw. Sorafenib (Nexavar®) as first-line therapy
2. with Sunitinib (Sutent®), Pazopanib (Votrient ®) bzw. Sorafenib (Nexavar®) as second-line therapy after failed first-line therapy, who are off therapy for at least 2 weeks
* no contraindications against contrast-enhanced CT
* obtained informed consent to participate in the study
Exclusion Criteria:
Patients who have:
* not given informed consent
* known iodine allergy
* high grade renal insuffiency (eGFR \< 30ml/min) not on dialysis
* overt hyperthyreoidism
* singular metastases \<1cm in diameter
* an increase of their baseline creatine levels of \>20% between CT examinations
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT02086734
Study Brief:
Protocol Section:
NCT02086734